Experimental Design: For 81 newly diagnosed DLBCL patients, treated with Rituximab and CHOP/CHOP-like regimen, TMTV was computed using the 41% SUVmax thresholding method. According to the gene expression profile, determined using DASL (cDNA-mediated Annealing, Selection, Ligation and extension) technology, a subset of 57 patients was classified in GCB or ABC subtypes and MYC or BCL2 overexpressed.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most frequent non Hodgkin lymphoma (NHL), making up about 30% to 40% of diagnoses of NHL worldwide. The addition of rituximab to the CHOP backbone has improved the outcome of patients with DLBCL, from 45% 5-year PFS to 60% (1) (2) (3) . However, despite these improvements, over 30% of patients treated with R-CHOP or R-CHOP like chemotherapy will not respond or will relapse with resistant disease (4), with a majority of patients succumbing to their disease (1) (2) (3) . These patients with a high risk of treatment failure or relapses cannot be selected accurately by the classic prognostic factors and new prognostics factors are under investigation at diagnosis, to identify these high risk patients, which could benefit from an alternative therapeutic strategy.
FDG-PET/CT is now recommended as the best imaging tool in DLBCL and is used routinely for staging and response assessment (5) . Prospective (6) and retrospective (7-9) studies have suggested that end treatment and early PET could be used as good prognosticators of outcome. New promising PET metrics derived from baseline PET, allowing an estimate of tumor burden and metabolism, are proposed as biomarkers: the Total Metabolic Tumor Volume (TMTV) which is the sum of the regions of the local tumors with FDG uptake; the Total Lesion Glycolysis (TLG) which is the sum of these regions weighted by the intensity of their FDG uptake. At least retrospective studies have shown that a high TMTV was significantly associated with a worse PFS and/or OS in DLBCL (10, 11) but also in other type of lymphoma, in Primary Mediastinal large B cell lymphoma (12), in Hodgkin lymphoma (13) and in Peripheral T cell lymphoma (14).
The Gene expression profiling (GEP) of DLBCL tumors has also been reported as a prognostic factor by identifying two main subtypes (15) : those with gene expression reminiscent of germinal center (the GCB group) and those with gene expression similar to activated B cells (the ABC group). The cell of origin (COO) phenotype has been demonstrated as a strong prognostic biomarker by different assays. Patients with GCB subtype have significantly better clinical outcome than those with an activated B-cell phenotype (15) (16) (17) . Similarly, DLBCL with MYC and BCL2 overexpression termed Dual expressors (DE) is usually considered as a subgroup with a poor outcome (18) (19) (20) . Therefore molecular data, even if they are not used routinely, are potentially predictive biomarkers. The combination between these two prognosticators, FDG-PET/CT and gene expression profiling, has been recently investigated and our group has suggested that the response to treatment evaluated by interim PET combined with molecular profile could gain some interest in risk stratification (21) .
Research. The aim of the present study was to investigate the prognostic impact of baseline PET/CT metrics, including TMTV in patients with newly diagnosed DLBCL and their added value to molecular characteristics, including ABC/GCB status, MYC and BCL2 overexpression. The expression profile of 18 GCB/ABC related genes, previously defined by Wright and colleagues (22) , were determined, when frozen tissues were available, using DASL (cDNAmediated Annealing, Selection, Ligation and extension) technology. According to the GEP, patients were classified as GCB or ABC subtype, as previously reported (21) . MYC and BCL2 mRNA expression were also determined by DASL technology.
Methods
The study was conducted in accordance with the precepts of the Helsinki declaration and received approval by our institutional review board with a waiver of informed consent due to its retrospective nature.
PET/CT Parameters
All patients underwent FDG-PET before the onset of chemotherapy. They were asked to fast for at least 6 h before the injection of 18F-FDG and to have blood glucose under 11mmol/L.
PET data were acquired for the mid-thigh toward the base of the skull, 60-70 minutes after injection of a weight adjusted dose of 4-5 MBq/kilogram, on the Biograph 16 Siemens integrated PET CT scanner in the nuclear medicine department. volume of interest was set around each lesion (node or organ involvement) as previously described (10, 13, 23). Bone marrow involvement was included in volume measurement only if there was focal uptake. Spleen was considered as involved if there was focal uptake or diffuse uptake higher than 150 % of the liver background; (2) The TLG was the sum of the product of the metabolic volume of each local tumor times its SUVmean (TLG=∑MTV L x SUVmean L ); (3) The patient SUVmax was the highest SUVmax measured in the tumor sites.
Statistical analysis
The threshold to determine optimal cut-off values of the quantitative parameters for survival prediction was tested by Receiver Operating Curve (ROC) and by X-stile ® analysis. Overall Survival (OS) and PFS were defined according to the revised NCI criteria (24) . Survival functions were estimated using the Kaplan-Meier (KM) method and compared using the logrank test. Multivariate analyses were performed using a Cox proportional-hazards model.
Characteristics of population were compared between groups, using Fisher or Chi2 test appropriately. Differences between the results of comparative tests were considered significant if the two-sided p value was less than 0.05. Statistical analysis was conducted using MedCalc (MedCalc Software, Ostend, Belgium), and S-Plus7 software (Insightful, USA).
Results
81 patients with a median age of 66 years (range 22-87 years ) were enrolled: 80% had stage III/IV, 73% an elevated LDH, and 2/3 (68%) an IPIaa greater than 1. Median follow up was 64 months (7-129 months). Relapse or progression occurred in 34 patients at a median of 11 months after diagnosis and 31 patients died at a median of 17 months. The 5y-PFS was 60%
and the 5y-OS was 63% in the whole population. 60 patients were treated by R-CHOP chemotherapy regimen (including 5 R-mini CHOP) and 21 by R-ACVBP. 57 patients had frozen material allowing molecular analysis. Their characteristics did not differ in age stage, IPI and treatment allocation from the whole population (S1).
Quantitative PET parameters
In the whole population, the mean TMTV was 471 cm 3 (median 320 cm 3 , 25th-75th percentiles 106-668 cm 3 ). There was a continuous increased of risk with TMTV for PFS and OS with a Cox model (p=0.043 and p=0.031 respectively). X-tile® and ROC analysis revealed that the optimal TMTV cut-off value was 300 cm 3 for both estimating PFS and OS (figure 1). Areas under the raw ROC curves were 0.69 (p=0.0012) for PFS and 0.68 (p=0.0037) for OS. The 300 cm 3 cut-off value had a sensibility and a specificity of 73.5% and 63.8% for PFS and 74.2% and 62% for OS respectively. Kaplan Meier curves shown thatTMTV, using this cut off, was a strong prognostic factor of both PFS and OS. A high TMTV (TMTV> 300cm 3 , n=43) was predictive of both PFS and OS at univariate level, and also for OS at multivariate level when TMTV was adjusted for baseline IPIaa risk groups (table 2) . The 5-year estimates of PFS was 42% in the high metabolic burden group compared with 75% in the low metabolic burden goup (p=0.0023, HR=3.0). Patients with a high TMTV had a 5-year OS of 46% whereas 78% for patients with a low TMTV (p=0.0047, HR=3.0) (figure 2). The 550cm 3 cut off, already proposed in DLBCL (10) was also able to divide our population on PFS and OS. Even its specificity was better (79% and 76%), its sensitivity was lower than the sensitivity of the 300cm 3 threshold (50% for PFS and 48% for OS). Moreover, the separation of two groups of patients with different PFS and OS was less significant (HR=2.59 and HR=2.33 respectively).
Patients with a high TMTV had a more advanced disease, with significantly more advanced stage and Bulky disease (defined by a long axial nodal mass greater than 10cm). A strong correlation was observed between IPIaa and TMTV: more than 90% of patients with high TMTV had an IPIaa>1 (table 1) . No significant difference of ABC/GCB subtypes, MYC or BCL2 overexpression, or chemotherapy regimens have been observed between low or high TMTV groups (table 1) . Unlike TMTV, Bulk measurement was not predictive of outcome.
Age was strongly associated with bad prognosis (p=0.001 on PFS and p=0.0035 on OS using Cox model). TMTV and age were two independent prognostic factors of PFS and OS, without significant interaction on multivariate analysis, treating these variables either as continuous (p=0.03 and p=0.024 for TMTV; p=0.001 and p=0.0034 for age respectively) or dichotomized (p=0.0033 and p=0.0075 for TMTV > 300 cm3 respectively; p=0.0038 and p=0.0065 for age >60 years old).
The median TLG was 3677 (25th-75th percentiles 1066-6096). The ROC curve analysis showed an optimal cut-off value of 3904, for both PFS (p=0.0007) and OS (p=0.0042). A high TLG (n=36) was predictive of a higher disease progression rate (5-year PFS=41% vs.
72% for patients with low TLG, p=0.0016) and a worse survival (5-year OS 45% vs 73%, p=0.014). However TLG appeared less predictive of PFS and OS in univariate analysis compared to TMTV ( Patient SUVmax, with a median of 18 (range: 4.6 to 45), was not related with outcome. No significant difference of SUVmax distribution has been found between patients with a high TMTV (median of 19.6, range 7.3-36.3) and patients with a low TMTV (17, 4.6-45).
Molecular analysis
In the subset of patients where analysis of tumor RNA was available, the GCB/ABC phenotype was predictive of the outcome. As expected, patients with ABC subtype (n=27) had a lower PFS than patients with GCB subtype (n=30) (5-year PFS 38% vs. 69%, p=0.019) and a worse OS (5-year OS : 37% vs 73%, p=0.0046) ( figure 3A, table 2 ).
The optimal cut offs determined by ROC and X-tile analysis for MYC and BCL2 overexpression were 4800 and 11800 respectively, very close from the median (4660 and 10948, with a range of 1656-12249 and 3448-12985 respectively). Patients with overexpression of MYC (n=26) had an increased risk of relapse or progression (p=0.0032) and a reduced survival rates (p=0.0004), with a 5-y PFS of 31% and 5-year OS of 31% in contrast 72% and 75% respectively for the others patients (figure 2B). In a sub analysis, MYC was predictive of outcome for AB patients (PFS 70% vs16%, p=0.019, HR=3.8; OS 70% vs 16%, p=0.014, HR=4.1). It was not significant in GCB subtype.
Over expression of BCL2 (n=12) was also related with a poor outcome (PFS: p=0.0001; OS: p=0.01) (figure 3 C).
Interestingly, MYC overexpression appeared to be more frequent in ABC subtype (65%) as well as BCL2 overexpression (75%) compared with GCB subtype.
Combining MYC and BCL2 expression allowed individualizing a subset of 9 patients with a double over expression (DE), with a dismal outcome: at 5 year, they relapsed and died (figure 3 D). Eight out of the 9 patients had an ABC subtype.
Combining TMTV with molecular parameters TMTV allowed a stratification of ABC/GCB patients (p=0.013 for PFS and p=0.0036 for OS): GCB patients with low TMTV (n=15) had a 87% 5-year PFS and 87% 5-year OS compared to 53% and 60% for GCB with high TMTV (n=15); values for ABC patients with TMTV≤300cm3 (n=11) were 50% and 60% compared to 30% and 23% for ABC with high TMTV (n=16) (figure 3 A).
Combining MYC with TMTV split the population in 3 risk groups: MYC negative patients with a low TMTV (n=16, 5y-PFS of 93% and 5y-OS 93%); MYC negative patients with a high TMTV (n=15, 45% and 55%); MYC positive patients whatever their TMTV0 (n=26, 31% and 31%), p=0.0011 and p=0.0005 respectively (figure 2 B) . Similarly, TMTV allow a 
-PFS and OS (figure C).
A high TMTV individualized also in DE negative patients a subset of patients with a worse outcome, 5-year PFS and OS of 50% and 49%, compared with 81% 5y-PFS and OS.
Discussion
The current study confirms the strong prognostic value of baseline TMTV in patients with DLBCL. Quantifying the volume rather than the single largest diameter of the mass gives a more relevant estimation of tumour burden than the bulk for prognostic purposes, particularly in advanced disease.
Different methods have been proposed to calculate the volume-based PET parameters either in solid tumors or in different subtypes of lymphoma. We used a 41% SUVmax threlshold as recommended by European guidelines (25) , and already tested in HL, DLBCL (23) . In the present study, a tumour volume greater than 300 cm 3 was associated with a dismal outcome.
Patients with TMTV>300 cm 3 had a significantly shorter 5-year PFS (43%) and 5-year OS (46%) than those with TMTV≤300 cm 3 (76% and 78% respectively). This optimal threshold is different from the optimal thresholds reported in DLBCL by two other studies either using the same or different methods, i.e 550cm 3 in 114 patients or 220 cm 3 in 169 patients (10).
These different cut-offs could be attributed to differences in the distribution of patient's age, stage and treatment included in these retrospective series. For instance, the lower optimal threshold observed in our population compared to the 550 cm 3 reported by Sassanelli et al.
might be explained by the older age of our patients. In their study, the median age was 56 years with 21 % of patients over 60 years compared to a median of 66 years old with 63% of patients >60 years in the present study. Indeed a lower value of tumor burden is probably sufficient to discriminate patients with good or bad prognosis in elderly. The number of events was also higher in our group (30% vs 20%), most of events occuring in oldest patients.
In addition in both study there is a continuous increase of risk with the increase of TMTV .
The 550cm 3 could be applied in our population with a better specificity but a much lower sensitivity and would separate the survival curves of patients with low and high volumes albeit with less significance than the 300cm 3 .
The 220cm 3 predictive of PFS and OS, as Kim et al. (26) have already reported, but was less significant than TMTV.
We also confirmed in the present study that ABC phenotype (16, 17) , MYC (27, 28) while TMTV stratify outcomes for individuals with a particular disease (prognostic factor).
As COO phenotype, TMTV is a "true" prognosticator since it is available at baseline and independent from treatment. Therefore it seems relevant to combine molecular profiles obtained at diagnosis with baseline PET metrics derived from tumor metabolism, with the aim to develop new prognostic models.
Research. 
Ours results suggested that TMTV gave added prognostic value on molecular risk analysis, either on ABC/GCB profiles or on negative MYC, BCL2 or double overexpression.
Combining COO phenotype with TMTV stratified the population into 4 different prognostic groups. Among GCB-DLBCL patients, usually considered as low risk, a high TMTV brings down the 5-year PFS from 87% to 53%, the 5-year OS 87% to. 60%. Conversely, in ABC patients who are characterized by an unfavourable outcome, TMTV individualize a subset of patients with a better outcome, those with a low TMTV, with a 5-year PFS of 50% and 5-year OS of 60%. ABC patients with a high TMTV displayed a very poor outcome, with 5-year PFS of 30% and 5-year OS of 23%.
MYC expression associated with TMTV allowed a more accurate selection of patients than MYC alone dividing MYC negative patients according to TMTV into distinct prognostic groups. In MYC negative patients, representing more than half of the population (55%), a high TMTV individualized a group of patients, 26% of the whole population, with an inferior outcome than foreseen. Similarly TMTV discriminate in BLC2 negative patients, which represent 79% of the population, one half of patients with a dismal outcome. The impact of TMTV is even more striking in patients without double MYC/BCL2 overexpression (84% of patients) identifying 45% patients from the whole population with an inferior prognosis.
The current study highlighted the benefit of an integrative approach, including molecular data and quantitative PET metrics, at diagnosis for DLBCL patients. TMTV could reclassify an important subset of patients: in the GCB group, in the MYC and BLC2 negative groups and in the non-dual expressor patients. TMTV allows identifying in patients with negative molecular biomarkers a subpopulation which can no longer be considered at low risk.
The limitation of this study would be in the determination of the TMTV cut off. The few studies (10, 11, 39) which have reported the prognostic value of TMTV on DLBCL have included a small number of patients (less than 150 patients) and are retrospective which can explain the cut off discrepancies. It encouraged enlarging the analysis of the relevance of TMTV in a large cohort in order to stabilize the optimal threshold. However the choice of the cut off for a trial would depend on its primary objective which can be escalating of deescalating the treatment. This could be compared to the use of Deauville 5 point scale for interim PET guided therapy. In RAPID (40) a de-escalating trial in Hodgkin lymphoma a cut off over 2 was used to declare a patient positive in order to select for de-escalation patients truly negative. By contrast in RATHL (41) an escalating trial a cut off over 3 was used to score positivity to be more confident that patients were truly positive to escalate the treatment.
Therefore the TMTV threshold should be adjusted to the objective of the trial: lower volume threshold for getting higher sensitivity, higher volume threshold for getting higher specificity. 
